New therapies in multiple myeloma

被引:46
|
作者
Merchionne, F. [1 ]
Perosa, F. [1 ]
Dammacco, F. [1 ]
机构
[1] Univ Bari, Sch Med, Sect Internal Med & Clin Oncol, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy
关键词
multiple myeloma; therapy; thalidomide; lenalidomide; bortezomib;
D O I
10.1007/s10238-007-0134-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The melphalan-prednisone regimen has been considered as standard therapy for patients with multiple myeloma (MM) for many years. Recently, high-dose chemotherapy with stem-cell support has extended progression-free survival and increased overall survival, and it is now considered conventional therapy in younger patients. However, most patients relapse and the salvage treatment is not very effective. New active drugs, including immunomodulatory agents, thalidomide (Thal) and lenalidomide, and the proteasome inhibitor bortezomib, have shown promising anti-myeloma activity. These novel treatments are aimed at overcoming resistance of tumour cells to conventional chemotherapy, acting both directly on myeloma cells and indirectly by blocking the interactions of myeloma cells with their local microenvironment and suppressing growth and survival signals induced by autocrine and paracrine loops in the bone marrow. Thal has been widely studied, mostly in combination regimens in patients with relapsed MM and, more recently, in front-line therapy, showing efficacy in terms of response rate and event-free survival. Bortezomib has been found to possess remarkable activity, especially in combination with other chemotherapeutic agents, in relapsed/refractory and newly diagnosed MM, as well as in patients presenting adverse prognostic factors. Lenalidomide, in combination with dexamethasone, is showing high overall response rates in relapsed and refractory MM and promising results also in first-line therapy. In this paper, the results of the most significant trials with Thal, bortezomib and lenalidomide are reported. Several ongoing clinical studies will hopefully allow the identification of the most active combinations capable of improving survival in patients with MM.
引用
收藏
页码:83 / 97
页数:15
相关论文
共 50 条
  • [1] New therapies in multiple myeloma
    F. Merchionne
    F. Perosa
    F. Dammacco
    Clinical and Experimental Medicine, 2007, 7 : 83 - 97
  • [2] New therapies in multiple myeloma
    Goldschmidt, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 322 - 322
  • [3] New Therapies Approved for Multiple Myeloma
    Terrie, Yvette C.
    US PHARMACIST, 2016, 41 (10)
  • [4] New Biological Therapies for Multiple Myeloma
    Garfall, Alfred L.
    ANNUAL REVIEW OF MEDICINE, 2024, 75 : 13 - 29
  • [5] Multiple myeloma therapies
    Matthew Strobeck
    Nature Reviews Drug Discovery, 2007, 6 : 181 - 182
  • [6] New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma
    Abdallah, Nadine
    Kumar, Shaji K.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (02) : 511 - 532
  • [7] How best to use new therapies in multiple myeloma
    Dingli, David
    Rajkumar, S. Vincent
    BLOOD REVIEWS, 2010, 24 (03) : 91 - 100
  • [8] Promising therapies in multiple myeloma
    Bianchi, Giada
    Richardson, Paul G.
    Anderson, Kenneth C.
    BLOOD, 2015, 126 (03) : 300 - 310
  • [9] Current Therapies for Multiple Myeloma
    Tariman, Joseph D.
    JOURNAL OF INFUSION NURSING, 2007, 30 (02) : 113 - 118
  • [10] Targeted therapies in multiple myeloma
    Kastritis, Efstathios
    Charidimou, Andreas
    Varkaris, Andreas
    Dimopoulos, Meletios A.
    TARGETED ONCOLOGY, 2009, 4 (01) : 23 - 36